Table 2.
Differences in dosages and survival in patients with transdermal opioids with additional peroral analgesics (with an equianalgesic ratio of 1:80 for buprenorphine).
| Combination | Number of patients | Initial dose | Final dose | Diff. (%) | Survival (SD) | Performance score |
|---|---|---|---|---|---|---|
| Fentanyl + PO opioids | 222 | 110.54 ± 97.66 | 154.77 ± 103.48 | 44.23 (40.0) | 16.55 ± 19.28 | 3.15 ± 0.96 |
| Buprenorphine + PO opioids | 68 | 117.35 ± 95.49 | 151.74 ± 96.49 | 34.39 (29.3) | 16.48 ± 19.14 | 3.26 ± 0.80 |
| P value | - | 0.37 | 0.92 | 0.81 | 0.89 | 0.60 |
| Fentanyl without PO opioids | 70 | 88.28 ± 67.93 | 111.09 ± 64.50 | 22.80 (25.8) | 15.91 ± 19.75 | 3.36 ± 0.92 |
| Buprenorphine without PO opioids | 25 | 60.67 ± 50.70 | 84.86 ± 40.39 | 24.19 (39.9) | 10.88 ± 13.07 | 3.20 ± 1.00 |
| P value | - | 0.68 | 0.74 | 0.57 | 0.22 | 0.48 |
| Fentanyl + NSAID | 108 | 107.36 ± 99.35 | 160.13 ± 104.27 | 52.77 (49.1) | 19.76 ± 21.29 | 3.05 ± 0.95 |
| Buprenorphine + NSAID | 33 | 102.78 ± 78.09 | 140.33 ± 79.26 | 37.56 (36.5) | 14.96 ± 13.20 | 3.24 ± 0.79 |
| P value | - | 0.81 | 0.48 | 0.65 | 0.21 | 0.39 |
| Fentanyl without NSAID | 184 | 103.95 ± 87.33 | 135.01 ± 91.99 | 31.07 (29.89) | 14.43 ± 17.89 | 3.28 ± 0.96 |
| Buprenorphine without NSAID | 60 | 101.75 ± 95.34 | 130.15 ± 95.80 | 28.39 (27.90) | 14.98 ± 20.02 | 3.25 ± 0.89 |
| P-value | - | 0.85 | 0.89 | 0.65 | 0.80 | 0.59 |
Doses are presented oral morphine equivalents, mg/day. NSAID = nonsteroidal anti-inflammatory drugs. PO = per oral. The performance score is rated from 0 to 4, with 0 being fully mobile patients and 4 being bedridden patients.